Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong; Hui-Min Lei; Qian Liang; Ya-Bin Tang; Ye Zhou; Yang Wang; Shengzhe Zhang; Wen-Bin Li; Yunguang Tong; Guanglei Zhuang; Liang Zhang; Hong-Zhuan Chen; Liang Zhu; Ying Shen

doi:10.7150/thno.58558

Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Theranostics. 2021 Feb 9;11(8):3963. doi: 10.7150/thno.58558. eCollection 2021.

Authors

Jiang-Kai Dong^{1

2}, Hui-Min Lei^{1

2}, Qian Liang^{1

2}, Ya-Bin Tang^{1

2}, Ye Zhou^{1

2}, Yang Wang^{1

2}, Shengzhe Zhang³, Wen-Bin Li¹, Yunguang Tong^{4

5}, Guanglei Zhuang³, Liang Zhang^{1

2}, Hong-Zhuan Chen^{1

2}, Liang Zhu^{1

2}, Ying Shen^{1

2}

Affiliations

¹ Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
² Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.
³ State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
⁴ Basic Medical College, Xinxiang Medical University, Xinxiang 453003, Henan, China.
⁵ Department of Medicine, Cedars-Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, United States.

Abstract

[This corrects the article DOI: 10.7150/thno.23177.].

Publication types

Published Erratum